Drug intelligence / Profile preview

XCEL-M-ALPHA

Development stage: Phase 2
Modality: Cell Therapies
Administration: Intraarticular

Overview

XCEL-M-ALPHA is an ex vivo expanded autologous bone marrow mesenchymal stromal cell (MSC) product developed for the treatment of knee osteoarthritis. It is administered as a single intra-articular infusion. Clinical trials have shown it to be safe and well-tolerated, with benefits including long-lasting pain reduction, improved quality of life, and signs of cartilage regeneration. The product utilizes the multilineage differential potential, immunosuppressive and self-renewal capabilities of bone marrow MSCs.

Brand names: XCEL-M-ALPHA
Other names: Autologous bone marrow derived ex vivo expanded mesenchymal stromal cellsXCEL-M-ALPHA and standard rehabilitation

Beyond the preview

Go deeper on XCEL-M-ALPHA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XCEL-M-ALPHA.

Explore the full profile